|| List of recent Peptide-related patents
This document provides methods and materials related to transcription terminators. For example, methods and materials related to transcription terminators and nucleic acid molecules (e.g., vectors and constructs) that contain a nucleic acid sequence that encodes a polypeptide operably linked to a transcription terminator are provided.
|Plants having enhanced yield-related traits and a method for making the same|
The present invention relates generally to the field of molecular biology and concerns a method for enhancing various plant yield-related traits by modulating expression in a plant of a nucleic acid encoding a rhl1 (root hairless 1) polypeptide, a tgase (transglutaminase) polypeptide, a try-like (tryptichon) polypeptide, or a bzr (brassinazole-resistant) polypeptide. Constructs useful for performing the methods, as well as plants having enhanced various plant yield-related traits thus obtained, are also provided..
|Method for the alteration of plants using cle polypeptides/peptides|
The present invention relates to altering the biomass and/or structure of a plant, in order to maximise its potential as a source of feedstock or increase its potential as a feedstock for the paper industry. Cle41 and/or cle42 are used to manipulate growth and structure of the vascular tissue of the plant.
|Family of pesticidal proteins and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided.
|Polynucleotides encoding enzymes from the jute lignin biosynthetic pathway|
Disclosed are polynucleotides encoding polypeptides that comprise the biosynthetic pathway for lignin in the jute plant. The present invention relates generally to the field of plant lignin biosynthesis genes, polypeptides encoded by such genes, and the use of such polynucleotide and polypeptide sequences for controlling plant lignin production.
|Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same|
A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid.
|Synthetic matrix for controlled cell ingrowth and tissue regeneration|
Biomaterials containing a three-dimensional polymeric network formed from the reaction of a composition containing at least a first synthetic precursor molecule having n nucleophilic groups and a second precursor molecule having m electrophilic groups wherein the sum of n+m is at least five and wherein the sum of the weights of the first and second precursor molecules is in a range from about 8 to about 16% b weight of the composition, preferably from about 10 to about 15%, more preferably from about 12 to about 14.5% by weight of the composition. In one embodiment, the first and second precursor molecules are polyethylene glycols functionalized with nucleophilic and electrophilic groups, respectively.
|Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders|
The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides, to methods for preparing such amino acid sequences and polypeptides, to host cells expressing or capable of expressing such amino acid sequences or polypeptides, to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells, and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.. .
|Interleukin-2 muteins for the expansion of t-regulatory cells|
Provided herein are il-2 muteins and il-2 mutein fc-fusion molecules that preferentially expand and activate t regulatory cells and are amenable to large scale production. Also provided herein are variant human igg1 fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at n297.
|Agents and methods for the expression and secretion of peptides and proteins|
The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin a and/or hemolysin c-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.. .
|Cell killing fusion peptide exhibiting tumor cell-specific necrosis induction and tumor regression|
A cell-killing peptide, more specifically a cell-killing ckp fusion peptide (ctd7:ckp) is disclosed, wherein a cell-killing peptide (ckp) comprising 10 amino acids in mtd of noxa protein causing cell death, and 7 amino acids targeting a cancer cell are fused. The cell-killing ckp fusion peptide induces strong cell necrosis at various cancer cell lines (hela, hct116, mcf-7, a549, bjab, ct26, pc3 and the like) and shows strong tumor regression effect at a mouse tumor model using experimental animals, but does not show apoptosis at normal cells.
|Method for enhancing immune response with peptide|
An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant.
|Diketopiperazine forming dipeptidyl linker|
The invention relates to a method for homogeneous solution phase peptide synthesis (hspps) of a n-terminal peptide fragment pep-n and a c-terminal peptide fragment c-pep, with c-pep carrying a specific diketopiperazine (dkp) comprising c-terminal protecting group, which contains a handle group hg, with hg being connected to the c-terminus of the peptide fragmcnt; thereby this specific dkp comprising c-terminal protecting group can be selectively cleaved from the peptide as a conventionally used c-terminal protecting group. By the use of this dkp and hg comprising c-terminal protecting group, certain process steps in convergent peptide synthesis based on a combination of hspps and solid phase peptide synthesis (spps) can be avoided.
|Compositions and methods for the suppression of target polynucleotides from lygus|
Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the lygus genus, they are capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant.
|Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases|
Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as npra and nprc, or combinations of these therapies.
|Method for treating brain cancer using a novel tumor suppressor gene and secreted factor|
The present invention is directed to methods of using hss1 (hematopoietic signal peptide-containing secreted 1), hsm1 (hematopoietic signal peptide-containing membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.. .
|Fusion protein comprising circularly permuted form of trail/apo2l, coding gene and use thereof|
Provided is a fusion protein comprising circularly permuted form of trail, and the fusion protein contains circularly permuted form of trail and oligopeptides located at the n-terminus and/or c-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines.
|Kinase inhibitors and uses thereof|
The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population..
|Cell-penetrating peptides having a central hydrophobic domain|
The present invention discloses cell penetrating peptides (cpp or membrane translocating peptide) and their conjugates with cargo molecules. The peptides are useful as drug delivery systems, particularly as delivery vehicles for nucleotide-based theraputics, such as polynucleotides, oligonucleotides and peptide nucleic acids.
|Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer|
The invention provides methods for treatment of tissue factor (tf) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease.
|Compositions and methods for inhibition of mmp:mmp-substrate interactions|
The present invention provides compounds for disrupting the binding of a matrix metalloprotease (mmp) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the mmp's ability to cleave a substrate protein.
|Compounds for proteasome enzyme inhibition|
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of n-terminal nucleophile (ntn) hydrolases. The activities of those ntn having multiple activities can be differentially inhibited by the compounds described.
|Methods for selective targeting|
A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a kd in the range of about 10−7 to 10−10 m. Additionally claimed are the ligands identified according to the method..
|Methods for assessing risk for cardiac dysrythmia in a human subject|
The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing andersen's syndrome. A tissue sample from a patient is obtained and the dna or proteins of the sample isolated.
|Nanoporous substrates for analytical methods|
Nanoporous materials can be used to enrich samples for subsequent analysis of substances contained in the sample. The method is shown to enrich the yield of species in the low molecular weight proteome, allowing detection of small peptides in the low nanomolar range..
|Biocatalysts and methods for the synthesis of substituted lactams|
The present disclosure relates to transaminase polypeptides capable of aminating a dicarbonyl substrate, and polynucleotides, vectors, host cells, and methods of making and using the transaminase polypeptides.. .
|Polypeptides having cellobiohydrolase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Polypeptides having xylanase activity and polynucleotides encoding same|
Provided are isolated polypeptides having xylanase activity, catalytic domains and cellulose binding domains, and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains..
|Polypeptide variants with altered effector function|
The present invention concerns polypeptides comprising a variant fc region. More particularly, the present invention concerns fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the fc region thereof..
|Solubility enhancing peptide and use thereof|
The present invention relates to an isolated peptide consisting of the amino acid sequence of seq id no: 1. The present invention also relates to a method for increasing expression of a target protein using the peptide consisting of the amino acid sequence of seq id no: 1, comprising (a) fusing the peptide with the target protein to form a recombinant protein; and (b) expressing the recombinant protein by an expression host..
|Microorganism and method for overproduction of gamma-glutamylcysteine and derivatives of this dipeptide by fermentation|
The invention relates to a prokaryotic microorganism strain capable of overproducing γ-glutamylcysteine and its derivatives bis-γ-glutamylcystine and γ-glutamylcystine, which can be prepared from a parent strain, wherein said strain has a reduced cellular glutathione synthetase activity compared to the parent strain, and has a cellular γ-glutamylcysteine synthetase activity which is more greatly increased than in a strain with similarly reduced cellular glutathione synthetase activity.. .
|Enzymes for degrading organophosphates|
The present invention relates to enzymes capable of hydrolysing organophosphate (op) molecules. In particular, the invention relates to variants of the opda enzyme from agrobacterium that display improved activity when compared to the naturally occurring opda.
|Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis|
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue.
|Fluorescent two-hybrid (f2h) assay for direct visualization of protein interactions in living cells|
The present invention relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell or interacts with proteinaceous or non-proteinaceous structures accumulated at distinct sites in the nucleus of the cell; and (ii) a (poly)peptide specifically binding to gfp; (b) expressing in the same cell a second fusion protein comprising (i) gfp; and (ii) a bait (poly)peptide; (c) expressing in the same cell a third fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of gfp; and (ii) a prey (poly)peptide; and (d) detecting the fluorescence emission of the fluorescent parts of the second and the third fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. The invention also relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a fluorescent (poly)peptide; (ii) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell; and (iii) a bait (poly)peptide (b) expressing in the same cell a second fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of the fluorescent (poly)peptide comprised in said first fusion protein; and (ii) a prey (poly)peptide and (c) detecting the fluorescence emission of the fluorescent parts of the first and the second fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide.
|Methods for treatment of bacterial infections|
The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4→3 and 3→3 transpeptide cross-linkages, the formation of which are catalyzed by d,d- and l,d-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit l,d-transpeptidases, either alone or in combination with d,d-transpeptidase inhibitors, are provided herein.
|Functionalized nanoparticles for intracellular delivery of biologically active molecules|
Functionalized biocompatible nanoparticles capable of penetrating through a mammalian cell membrane and delivering intracellularly a plurality of bioactive molecules for modulating a cellular function are disclosed herein the functionalized biocompatible nanoparticles comprise: a central nanoparticle ranging in size from about 5 to about 50 nm and having a polymer coating thereon, a plurality of functional groups covalently attached to the polymer coating, wherein the plurality of bioactive molecules are attached to the plurality of the functional groups, and wherein the plurality of bioactive molecules include at least a peptide and a protein, and wherein the peptide is capable of penetrating through the mammalian cell membrane and entering into the cell, and wherein the protein is capable of providing a new functionality within the cell. The protein may be a transcription factor selected from the group consisting of oct4, sox2, nanog, lin28, cmyc, and klf4..
|Method to induce neovascular formation and tissue regeneration|
The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (vegf), or that encodes a polypeptide comprising an active site of the vegf. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte.
|Ehrlichia ewingii proteins, nucleic acids, and methods of their use|
The novel omp-1 gene cluster encoding twenty one ehrlichia ewingii (ee) proteins was isolated and sequenced completely. This invention relates to isolated e.
|Modified streptococcus pneumonia pneumolysin (ply) polypeptides|
This disclosure relates to modified streptococcus pneumonia pneumolysm (ply) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by s. Pneumonia the modified pneumolysm proteins comprise ammo acid substitutions at threonine 65, glycine 293 and cysteine 428 nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.
|Modification of helper t cell-inducing polypeptide|
The present invention provides a tumor antigen-specific th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using same.. .
The present invention provides nanoparticles and compositions comprising such nanoparticles, as well as methods for intracellular delivery of peptides, and methods of producing nanoparticles and related products. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises a peptide of choice that is covalently linked to the core via a second linker.
|Mutant hsp70i to prevent autoimmune disease|
A vaccine and method of treatment suitable for treating autoimmune diseases, such as vitiligo, by using variant peptides representing a sequence of amino acids found in heat shock protein 70. The vaccine includes a peptide derived from inducible heat shock protein 70 and a plasmid containing a full inducible heat shock protein 70 dna sequence encoding the peptide..
The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.. .
|Pharmaceutical composition for treatment and/or prevention of cancer|
According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of caprin-1, wherein caprin-1 is represented by any of the even-numbered sequences of seq id nos: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by seq id no: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence..
|B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide|
The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the b7-h6 polypeptide.
|Prevention and treatment of amyloidogenic disease|
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient.
|Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto|
The present invention features inter alia polypeptides comprising heterodimeric fc regions. In addition, the instant invention provides methods for treating or preventing a disease or disorder in subject by administering the polypeptides of the invention to said subject..
|Biological materials related to c-met|
The present invention relates to biological materials related to c-met possibly in combination with vegf and/or egfr, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-met therapy are also described and provided..
|Compositions, methods and uses for alpha-1 antitrypsin fusion molecules|
Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment.
|Pseudomonas aeruginosa oprm epitopes for use in diagnostics and therapeutics|
The present invention relates to a peptide antigens derived from pseudomonas aeruginosa outer membrane protein oprm for use in the diagnosis of pseudomonas aeruginosa infection and/or prevention/treatment of diseases associated with pseudomonas aeruginosa infection. Methods of inducing an immune response to pseudomonas aeruginosa using peptide antigens derived from the oprm outer loops as well as derivatives or fragments thereof are also encompassed by the present invention.
|Methods for the prevention or treatment of vessel occlusion injury|
This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof wherein the peptide is d-arg-26-dmt-lys-phe-nh2 (ss-31)..
|Method for the treatment of pulmonary disease and method of producing proteins of use therein|
Methods of treating a subject with pulmonary disease by administering a therapeutically effective amount of a defensin polypeptide including at least one arginine residue susceptible to adp-ribosylation and nicotinamide adenine dinucleotide (nad), are described. The polypeptide and/or nad can be administered via inhalation.
|Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof|
The invention relates to the discovery of a novel chondroitinase glycoproteins (chasegps), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase glycoproteins require both a substantial portion of the catalytic domain of the chasegp polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity.
|Methods of inhibiting photoreceptor apoptosis|
The present invention provides methods to prevent photoreceptor death. In particular, the present invention provides peptides which prevent fas-mediated photoreceptor apoptosis..
|Pet tracer for imaging of neuroendocrine tumors|
There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (pet). The compound may thus be used for diagnosis of malignant diseases.